Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
| ▸ | CASR | P41180 | 2/20 | 0.37 |
| ▸ | METAP2 | P50579 | 5/20 | 0.36 |
| ▸ | METAP1 | P53582 | 5/20 | 0.36 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6652095 | 0.89 | CXCR4 (0.60) | CXCR4CASRMETAP2METAP1USP1 | |
| SCHEMBL6652792 | 0.86 | CXCR4 (0.58) | CXCR4CASRMETAP2METAP1USP1 | |
| SCHEMBL6655464 | 0.85 | CXCR4 (0.56) | CXCR4CASRMETAP2METAP1USP1 | |
| SCHEMBL6653532 | 0.83 | CXCR4 (0.54) | CXCR4CASRMETAP2METAP1USP1 | |
| SCHEMBL6656191 | 0.83 | CXCR4 (0.54) | CXCR4CASRMETAP2METAP1USP1 | |
| SCHEMBL6655038 | 0.83 | CXCR4 (0.54) | CXCR4CASRMETAP2METAP1USP1 | |
| SCHEMBL6677936 | 0.82 | CXCR4 (0.53) | CXCR4CASRMETAP2METAP1USP1 | |
| SCHEMBL6655027 | 0.81 | CXCR4 (0.51) | CXCR4CASRMETAP2METAP1PPARG | |
| SCHEMBL6651937 | 0.78 | CXCR4 (0.55) | CXCR4CASRMETAP2METAP1PPARG | |
| SCHEMBL6657908 | 0.78 | CXCR4 (0.56) | CXCR4CASRMETAP2METAP1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | KUREHA CORPORATION (JP) | 2004-12-16 | — | — | US | claimed |
| EP-1431290-A1 | NOVEL NITROGENOUS COMPOUND AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2004-06-23 | — | — | EP | claimed |
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | KUREHA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431290-A1 | NOVEL NITROGENOUS COMPOUND AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | NGLY1, NOD1, CCR1 | CXCR4 88/4885CASR 4811/4885METAP2 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.